Prevalence of Hepatitis A Virus Antibody in Portuguese Travelers: A New Paradigm
Autor(a) principal: | |
---|---|
Data de Publicação: | 2017 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130 |
Resumo: | Introduction: In Portugal, the prevalence of hepatitis A virus infection has decreased in the past decades, especially in young adults. The aim of this study was to detect the prevalence of antibody to hepatitis A virus in a population observed in our Travel Clinic.Material and Methods: Antibodies against hepatitis A, hepatitis B, hepatitis C and human immunodeficiency virus were tested using standard enzyme immunoassay in patients older than 18. The exclusion criteria were: prior vaccination for hepatitis A virus, previous diagnosis of infection with hepatitis B virus, hepatitis C virus and/or human immunodeficiency virus, foreign travelers and long-term expatriates. We applied an epidemiological survey and data was statistically analyzed with SPSS® 18.0.Results: In the 665 travelers studied, natural immunity to hepatitis A virus was present in 57.6% (n = 383). They were stratified into 8 age groups and for each one hepatitis A immunity was clarified: 5.0% (n = 1) in 18 - 25 years, 32.3% (n = 21) in 26 - 30 years, 40.9% (n = 47) in 31 - 35 years, 45.8% (n = 54) in 36 - 40 years, 68.7% (n = 79) in 41 - 45 years, 70.1% (n = 68) in 46 - 50 years, 80.8% (n = 63) in 51 - 55 years and 87.7% (n = 50) over 56 years old. In those who accepted further screening, positivity for hepatitis B core antibody was found in 0.6% (n = 3) travelers, hepatitis C virus infection in 1.1% (n = 6) and human immunodeficiency virus infection in 0.5% (n = 3) whose previous status was unknown. The most frequent travel destination was sub-Saharan Africa (72.6%; n = 483).Discussion: We found 49.1% (n = 260) travelers under 50 years old susceptible to hepatitis A virus infection and for those between 40 and 50 years, 30.7% (n = 65) still need vaccine protection.Conclusion: Across age groups there is a trend towards lower prevalence of hepatitis A virus antibody, in particular among youngsters, when compared with older Portuguese studies. |
id |
RCAP_3b79eb39db6a3b5946e4607a09cf6722 |
---|---|
oai_identifier_str |
oai:ojs.www.actamedicaportuguesa.com:article/8130 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Prevalence of Hepatitis A Virus Antibody in Portuguese Travelers: A New ParadigmSeroprevalência do Anticorpo do Vírus na Hepatite A em Viajantes Portugueses: Um Novo ParadigmaHepatitis AHepatitis A AntibodiesHepatitis A VirusHumanPortugalSeroepidemiologic StudiesTravelTravel MedicineViral VaccinesAnticorpos Anti-Hepatite AEstudos SeroepidemiológicosHepatite AMedicina do ViajantePortugalViagemVírus da Hepatite A HumanaIntroduction: In Portugal, the prevalence of hepatitis A virus infection has decreased in the past decades, especially in young adults. The aim of this study was to detect the prevalence of antibody to hepatitis A virus in a population observed in our Travel Clinic.Material and Methods: Antibodies against hepatitis A, hepatitis B, hepatitis C and human immunodeficiency virus were tested using standard enzyme immunoassay in patients older than 18. The exclusion criteria were: prior vaccination for hepatitis A virus, previous diagnosis of infection with hepatitis B virus, hepatitis C virus and/or human immunodeficiency virus, foreign travelers and long-term expatriates. We applied an epidemiological survey and data was statistically analyzed with SPSS® 18.0.Results: In the 665 travelers studied, natural immunity to hepatitis A virus was present in 57.6% (n = 383). They were stratified into 8 age groups and for each one hepatitis A immunity was clarified: 5.0% (n = 1) in 18 - 25 years, 32.3% (n = 21) in 26 - 30 years, 40.9% (n = 47) in 31 - 35 years, 45.8% (n = 54) in 36 - 40 years, 68.7% (n = 79) in 41 - 45 years, 70.1% (n = 68) in 46 - 50 years, 80.8% (n = 63) in 51 - 55 years and 87.7% (n = 50) over 56 years old. In those who accepted further screening, positivity for hepatitis B core antibody was found in 0.6% (n = 3) travelers, hepatitis C virus infection in 1.1% (n = 6) and human immunodeficiency virus infection in 0.5% (n = 3) whose previous status was unknown. The most frequent travel destination was sub-Saharan Africa (72.6%; n = 483).Discussion: We found 49.1% (n = 260) travelers under 50 years old susceptible to hepatitis A virus infection and for those between 40 and 50 years, 30.7% (n = 65) still need vaccine protection.Conclusion: Across age groups there is a trend towards lower prevalence of hepatitis A virus antibody, in particular among youngsters, when compared with older Portuguese studies.Introdução: A prevalência da hepatite A em Portugal tem diminuído nas últimas décadas, sobretudo nos jovens adultos. O objetivo deste estudo foi avaliar a prevalência do anticorpo contra o vírus da hepatite A numa população que recorreu à consulta de Medicina do Viajante.Material e Métodos: Avaliamos a serologia de hepatite A, hepatite B, hepatite C e do vírus da imunodeficiência humana, através de imunoensaio enzimático padrão, de viajantes com idade igual ou superior a 18 anos. Excluímos aqueles previamente vacinados contra o vírus da hepatite A, com diagnóstico prévio de infeção pelos vírus da hepatite B, hepatite C e/ou vírus da imunodeficiência humana, estrangeiros e emigrantes. Aplicamos um inquérito epidemiológico prospetivo e analisamos os dados estatisticamente com o SPSS® versão 18.Resultados: Participaram no estudo 665 viajantes, dos quais 57,6% (n = 383) eram imunes para o vírus da hepatite A. Foram estratificados por oito grupos etários e, para cada um, foi avaliada a presença de imunidade: 5,0% (n = 1) nos 18 - 25 anos, 32,3% (n = 21) nos 26 - 30 anos, 40,9% (n = 47) nos 31 - 35 anos, 45,8% (n = 54) nos 36 - 40 anos, 68,7% (n = 79) nos 41 - 45 anos, 70,1% (n = 68) nos 46 - 50 anos, 80,8% (n = 63) nos 51 - 55 anos e 87,7% (n = 50) com idade igual ou superior a 56 anos. Dos que aceitaram realizar rastreio, detetou-se o anticorpo hepatitis B core em 0,6% (n = 3) viajantes, infeção pelo vírus da hepatite C em 1,1% (n = 6) e pelo vírus da imunodeficiência humana em 0,5% (n = 3), cujos estados serológicos eram desconhecidos. O destino mais frequente foi a África Subsariana (72,6%; n = 483).Discussão: Detetamos 49,1% (n = 260) viajantes suscetíveis a infeção pelo vírus da hepatite A e o grupo dos 40 aos 50 anos de idade, 30,7% (n = 65) ainda necessita de proteção vacinal.Conclusão: A prevalência do anticorpo contra o vírus da hepatite A tem diminuindo na população Portuguesa, aumentando a suscetibilidade a esta infeção nas deslocações a áreas endémicas.Ordem dos Médicos2017-08-31info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfimage/jpegimage/jpegimage/jpegimage/jpegimage/jpegimage/jpegapplication/pdfapplication/vnd.openxmlformats-officedocument.wordprocessingml.documentimage/jpegimage/jpeghttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130oai:ojs.www.actamedicaportuguesa.com:article/8130Acta Médica Portuguesa; Vol. 30 No. 7-8 (2017): July-August; 534-540Acta Médica Portuguesa; Vol. 30 N.º 7-8 (2017): Julho-Agosto; 534-5401646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPengporhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/5103https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/8692https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/8693https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/8694https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/9080https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/9081https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/9082https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/9091https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/9261https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/9341https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/9342Direitos de Autor (c) 2017 Acta Médica Portuguesainfo:eu-repo/semantics/openAccessRocha, SóniaTejo, SandraFerreira, EugéniaTrindade, LuísRabadão, EduardoMarques, NunoSaraiva da Cunha, José2022-12-20T11:05:26Zoai:ojs.www.actamedicaportuguesa.com:article/8130Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:19:33.065603Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Prevalence of Hepatitis A Virus Antibody in Portuguese Travelers: A New Paradigm Seroprevalência do Anticorpo do Vírus na Hepatite A em Viajantes Portugueses: Um Novo Paradigma |
title |
Prevalence of Hepatitis A Virus Antibody in Portuguese Travelers: A New Paradigm |
spellingShingle |
Prevalence of Hepatitis A Virus Antibody in Portuguese Travelers: A New Paradigm Rocha, Sónia Hepatitis A Hepatitis A Antibodies Hepatitis A Virus Human Portugal Seroepidemiologic Studies Travel Travel Medicine Viral Vaccines Anticorpos Anti-Hepatite A Estudos Seroepidemiológicos Hepatite A Medicina do Viajante Portugal Viagem Vírus da Hepatite A Humana |
title_short |
Prevalence of Hepatitis A Virus Antibody in Portuguese Travelers: A New Paradigm |
title_full |
Prevalence of Hepatitis A Virus Antibody in Portuguese Travelers: A New Paradigm |
title_fullStr |
Prevalence of Hepatitis A Virus Antibody in Portuguese Travelers: A New Paradigm |
title_full_unstemmed |
Prevalence of Hepatitis A Virus Antibody in Portuguese Travelers: A New Paradigm |
title_sort |
Prevalence of Hepatitis A Virus Antibody in Portuguese Travelers: A New Paradigm |
author |
Rocha, Sónia |
author_facet |
Rocha, Sónia Tejo, Sandra Ferreira, Eugénia Trindade, Luís Rabadão, Eduardo Marques, Nuno Saraiva da Cunha, José |
author_role |
author |
author2 |
Tejo, Sandra Ferreira, Eugénia Trindade, Luís Rabadão, Eduardo Marques, Nuno Saraiva da Cunha, José |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Rocha, Sónia Tejo, Sandra Ferreira, Eugénia Trindade, Luís Rabadão, Eduardo Marques, Nuno Saraiva da Cunha, José |
dc.subject.por.fl_str_mv |
Hepatitis A Hepatitis A Antibodies Hepatitis A Virus Human Portugal Seroepidemiologic Studies Travel Travel Medicine Viral Vaccines Anticorpos Anti-Hepatite A Estudos Seroepidemiológicos Hepatite A Medicina do Viajante Portugal Viagem Vírus da Hepatite A Humana |
topic |
Hepatitis A Hepatitis A Antibodies Hepatitis A Virus Human Portugal Seroepidemiologic Studies Travel Travel Medicine Viral Vaccines Anticorpos Anti-Hepatite A Estudos Seroepidemiológicos Hepatite A Medicina do Viajante Portugal Viagem Vírus da Hepatite A Humana |
description |
Introduction: In Portugal, the prevalence of hepatitis A virus infection has decreased in the past decades, especially in young adults. The aim of this study was to detect the prevalence of antibody to hepatitis A virus in a population observed in our Travel Clinic.Material and Methods: Antibodies against hepatitis A, hepatitis B, hepatitis C and human immunodeficiency virus were tested using standard enzyme immunoassay in patients older than 18. The exclusion criteria were: prior vaccination for hepatitis A virus, previous diagnosis of infection with hepatitis B virus, hepatitis C virus and/or human immunodeficiency virus, foreign travelers and long-term expatriates. We applied an epidemiological survey and data was statistically analyzed with SPSS® 18.0.Results: In the 665 travelers studied, natural immunity to hepatitis A virus was present in 57.6% (n = 383). They were stratified into 8 age groups and for each one hepatitis A immunity was clarified: 5.0% (n = 1) in 18 - 25 years, 32.3% (n = 21) in 26 - 30 years, 40.9% (n = 47) in 31 - 35 years, 45.8% (n = 54) in 36 - 40 years, 68.7% (n = 79) in 41 - 45 years, 70.1% (n = 68) in 46 - 50 years, 80.8% (n = 63) in 51 - 55 years and 87.7% (n = 50) over 56 years old. In those who accepted further screening, positivity for hepatitis B core antibody was found in 0.6% (n = 3) travelers, hepatitis C virus infection in 1.1% (n = 6) and human immunodeficiency virus infection in 0.5% (n = 3) whose previous status was unknown. The most frequent travel destination was sub-Saharan Africa (72.6%; n = 483).Discussion: We found 49.1% (n = 260) travelers under 50 years old susceptible to hepatitis A virus infection and for those between 40 and 50 years, 30.7% (n = 65) still need vaccine protection.Conclusion: Across age groups there is a trend towards lower prevalence of hepatitis A virus antibody, in particular among youngsters, when compared with older Portuguese studies. |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017-08-31 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130 oai:ojs.www.actamedicaportuguesa.com:article/8130 |
url |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130 |
identifier_str_mv |
oai:ojs.www.actamedicaportuguesa.com:article/8130 |
dc.language.iso.fl_str_mv |
eng por |
language |
eng por |
dc.relation.none.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/5103 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/8692 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/8693 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/8694 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/9080 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/9081 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/9082 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/9091 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/9261 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/9341 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/9342 |
dc.rights.driver.fl_str_mv |
Direitos de Autor (c) 2017 Acta Médica Portuguesa info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Direitos de Autor (c) 2017 Acta Médica Portuguesa |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf image/jpeg image/jpeg image/jpeg image/jpeg image/jpeg image/jpeg application/pdf application/vnd.openxmlformats-officedocument.wordprocessingml.document image/jpeg image/jpeg |
dc.publisher.none.fl_str_mv |
Ordem dos Médicos |
publisher.none.fl_str_mv |
Ordem dos Médicos |
dc.source.none.fl_str_mv |
Acta Médica Portuguesa; Vol. 30 No. 7-8 (2017): July-August; 534-540 Acta Médica Portuguesa; Vol. 30 N.º 7-8 (2017): Julho-Agosto; 534-540 1646-0758 0870-399X reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799130645936472064 |